Showing 6531-6540 of 9299 results for "".
- SimySkin Launches New Age-specific Skincare Linehttps://practicaldermatology.com/news/simyskin-launches-new-age-specific-skincare-line/2459032/SimySkin™ is pleased to announce the launch of its premier skincare line, which includes age-specific advanced scientific ingredients and formulations that correct, repair and reverse signs of aging. SimySkin<
- Suneva Medical's Bellafill Approved to Treat Acne Scarshttps://practicaldermatology.com/news/suneva-medicals-bellafill-approved-to-treat-acne-scars/2459034/Suneva Medical, Inc.'s Bellafill® is now the only filler on the market approved for the treatment of acne scars. FDA granted approval for Bellafil
- AARS Grant Application Deadline Approachinghttps://practicaldermatology.com/news/aars-grant-application-deadline-approaching/2459031/The American Acne & Rosacea Society (AARS) offers Mentorship and Clinical Research Grants to assist committed, visionary professionals lead acne and rosacea research, practice and clinical science into the future. AARS has ext
- Revance Therapeutics Initiates BELMONT Phase 2 Active Comparator Trial of Injectable RT002https://practicaldermatology.com/news/revance-launches-phase-2-belmont-study/2459035/Specialty biopharmaceutical company Revance Therapeutics, Inc. has initiated the BELMONT trial, a Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and
- Alcohol Intake Not Linked to Early BCChttps://practicaldermatology.com/news/alcohol-intake-not-linked-to-early-bcc/2459036/Despite some trends suggesting that high alcohol use and high UV exposure may be associated with risk for early onset BCC in women, there is no statistically significant association between lifetime alcohol intake and early-onset BCC overall or in women only, new data from the
- Modernizing Medicine, Inc. Acquires Aesyntix Health, Inc.https://practicaldermatology.com/news/modernizing-medicine-inc-acquires-aesyntix-health-inc/2459037/Modermizing Medicine, Inc., creator of the Electronic Medical Assistant® (EMA™), completed an acquisition of Aesyntix Health, Inc. on
- FDA Approves Galderma's Soolantra to Treat Rosaceahttps://practicaldermatology.com/news/fda-approves-galdermas-soolantra-for-rosacea/2459038/The FDA approved Galderma’s Soolantra (ivermectin) Cream 1% for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea. R Recent studies have further solidified that generally harmless microscopic Demodex mites may also be a culprit. These mites are norma
- FDA Grants Bristol-Myers Squibb's Opdivo Accelerated Approval for Melanomahttps://practicaldermatology.com/news/fda-grants-bristol-myers-squibbs-opdivo-accelerated-approval-for-melanoma/2459039/The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilim
- Gary D. Monheit, MD Wins Top ASDS Honorhttps://practicaldermatology.com/news/gary-d-monheit-md-wins-top-asds-honor/2459040/Gary D. Monheit, MD is the “very honored” 2014 recipient of the American Society for Dermatologic Surgery's highest honor: the Samuel J. Stegman, MD, Award for D
- Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Studyhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-to-meet-with-fda-on-operational-aspects-of-pv-10-phase-3-melanoma-study/2459043/Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will be me